Healthcare Companies Report Product Availability, Earning Release Schedules, Event, and Stock Movements - Analyst Notes on Celgene, Vanda, Chelsea Therapeutics, Neurocrine Biosciences, and USANA

NEW YORK, April 14, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and USANA Health Sciences Inc. (NYSE: USNA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1050-100free

Celgene Corporation Analyst Notes 

On April 1, 2014, Celgene Corporation (Celgene) announced that it will host a conference call on April 24, 2014, at 9:00 a.m. ET, to discuss its Q1 2014 financial and operational results. The Company informed that interested parties can access a live webcast of the call via the Investor Relations page in Celgene's website. In other news dated March 24, 2014, Celgene announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast), its oral, selective inhibitor of phosphodiesterase 4 (PDE4) the treatment of adult patients with active psoriatic arthritis. According to the Company, OTEZLA® is the only FDA-approved oral treatment for psoriatic arthritis. The full analyst notes on Celgene Corporation are available to download free of charge at:

http://www.analystsreview.com/1050-CELG-14Apr2014.pdf

Vanda Pharmaceuticals, Inc. Analyst Notes 

On April 9, 2014, Vanda Pharmaceuticals, Inc. (Vanda) announced the availability of HETLIOZ™. According to the Company, HETLIOZ™ is the first treatment approved by the U.S. Food and Drug Administration (FDA) for Non-24-Hour Sleep-Wake Disorder (Non-24). The Company stated that it has launched HETLIOZSolutions™ to support and facilitate the treatment of totally blind people living with Non-24. The Company added that the HETLIOZSolutions™ will provide patients with a host of resources including information about Non-24 and HETLIOZ™, insurance support, overview of financial assistance programs, and pharmacy access. Mihael H. Polymeropoulos, M.D., Vanda's President and CEO, stated, "The availability of HETLIOZ marks a major milestone for totally blind people who have been without an approved, safe and effective treatment for Non-24. We are also excited to bring a broad range of services to patients through HETLIOZSolutions." The full analyst notes on Vanda Pharmaceuticals, Inc. are available to download free of charge at:

http://www.analystsreview.com/1050-VNDA-14Apr2014.pdf

Chelsea Therapeutics International Ltd. Analyst Notes 

On April 9, 2014, Chelsea Therapeutics International Ltd.'s stock went up by 3.94% to end the trading session at $5.54. Over the past six-month period, the Company's stock increased a 108.27%, compared to the Nasdaq Composite Index which went up by 13.76% during the same period. The full analyst notes on Chelsea Therapeutics International Ltd. are available to download free of charge at:

http://www.analystsreview.com/1050-CHTP-14Apr2014.pdf

Neurocrine Biosciences Inc. Analyst Notes 

On April 9, 2014, Neurocrine Biosciences Inc.'s stock went up by 3.34%, closing the day at $14.53. In the past three trading days, the Company's stock went up by 1.68%, compared to the Nasdaq Composite which reflected an increase of 1.36% during the same period. The full analyst notes on Neurocrine Biosciences Inc. are available to download free of charge at:

http://www.analystsreview.com/1050-NBIX-14Apr2014.pdf

USANA Health Sciences Inc. Analyst Notes 

On April 7, 2014, USANA Health Sciences Inc. (USANA) announced that three thousand people have shed more than 16,000 pounds in just three months under its RESET Challenge: Destination Transformation in an effort to support people from all walks of life in their weight loss efforts and overall well-being. According to USANA, more than $300,000 in prizes will be awarded to 23 grand prize winners of the RESET Challenge, including a shopping spree, makeover, and photoshoot. Doug Braun, USANA Chief Marketing Officer, stated, "The incredible results achieved from last year's challenge were more than we ever anticipated. We were excited to once again help thousands of individuals get healthy, maintain their health, and lose weight this year." The full analyst notes on USANA Health Sciences Inc. are available to download free of charge at:

http://www.analystsreview.com/1050-USNA-14Apr2014.pdf

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.analystsreview.com/

SOURCE Analysts Review